Story

The Full Story

Between FY2021 and today, Cooper has walked three very different corporate narratives: a COVID rebound built on silicone-hydrogel volume, a debt-funded acquisition spree centred on Generate Life Sciences and Cook Medical, and — since mid-FY2025 — a cost-out, cash-return, "eight consecutive earnings beats" story stitched together after two back-to-back organic guide cuts. Revenue growth has re-rated from 6–8% to 4–5%, the 13-quarter fertility double-digit streak was quietly retired in Q2 FY24, and two activists (Jana Partners, Browning West) are now pushing for a break-up of CooperVision and CooperSurgical. Management has defended every EPS line but conceded ground on every growth line — the current story is simpler, less stretched, and demonstrably less ambitious than the one pitched two years ago.

1. The Narrative Arc

The growth profile tells the story in one chart: FY21's 20% was a pandemic-rebound anomaly, FY22–FY24 settled into an 8–10% corridor that framed every earnings call, and FY25 collapsed to +4% — the structurally lower level management is now guiding (4.5–5.5% for FY26). The re-rating from "high single / low double-digit grower" to "mid-single-digit grower" is the single most important fact of the last five years.

**Four distinct arcs.** (1) FY21 COVID rebound + silicone-hydrogel tailwind. (2) FY22–FY23 debt-funded M&A build-out (Generate + attempted/restructured Cook Medical). (3) FY24 balance-sheet re-platform (stock split, new $2.3B revolver, ERP material weakness). (4) FY25–FY26 growth break, cost-out, capital return, activist arrival.

2. What Management Emphasized — and Then Stopped Emphasizing

Five patterns jump off the heatmap. (1) The double-digit organic boast — the signature line through Q1 FY24 — disappears after the fertility streak breaks. (2) Fertility streak framing was cited 13 straight quarters, then never cited again. (3) Margin, FCF, buybacks, and reorganization — the current "Cooper 2.0" narrative — all ramp simultaneously starting Q3 FY25, exactly as organic growth rolls over. (4) MyDay has been the one constant, moving from supporting player to lead; MiSight becomes a top-emphasis story only in Q4 FY25 (+37% in the quarter). (5) Capacity expansion — drumbeat for eight quarters — goes quiet once "completing" is reached in Q2 FY25, replaced by cost-out language.

3. Risk Evolution

What became more important. Tariffs graduated to a standalone risk header in FY24 and now rank among the top three in FY25, reinforced by explicit GM-drag language in Q4 FY25 and Q1 FY26 ("excluding the impact of tariffs, gross margin would have been flat"). Cybersecurity evolved from a generic paragraph in FY21 to a detailed disclosure including a dedicated team with CISSP/GIAC credentials (FY22), and then to a Section 524B FDCA medical-device cybersecurity framework (FY25) with formal SBOM obligations. EU MDR/IVDR compliance and the FDA LDT Final Rule peaked as risks in FY24; the LDT rule was vacated in March 2025 and rescinded in September 2025, softening that exposure.

What became less important. COVID-19 collapsed from the lead risk in FY21 to absorbed boilerplate by FY24. Brexit went from a dedicated section in FY21 to a single line by FY24. The Russia-Ukraine war header — introduced as a new standalone risk in FY22 — was folded back into generic "international conflicts" language in FY25.

What appeared fresh. The FY24 disclosure of a material weakness in IT general controls at CooperSurgical's US operations (tied to the ERP implementation that also broke the fertility double-digit streak in Q2 FY24) was a genuine red flag — remediated by end of FY25 but a reminder that the acquisition machine outran its integration controls. The FY25 workforce-optimization and severance language is new and directly tied to the $89M reorganization charge.

Paragard watch. Through five years, product-liability litigation has never been elevated to a named Risk Factor — it sits inside the generic "product liability claims" paragraph. The only escalation: FY24 and FY25 explicitly name "Paragard IUDs" inside direct-to-consumer marketing risk language, a subtle acknowledgment that plaintiff activity warrants a nameplate, but well short of specific claim counts or reserves.

4. How They Handled Bad News

Three episodes define the credibility stress test.

Episode 1 — Q2 FY24: the fertility streak breaks. CooperSurgical's 13-quarter double-digit fertility organic streak snapped to +4%, and management attributed it, almost in passing, to a distribution-center system upgrade.

"CooperVision returned to double-digit growth… unexpected challenges with a system upgrade in our US distribution center." — Q2 FY24, May 2024

This mattered because fertility was the signature growth anchor, and the explanation was narrow (one data centre) for a reversal that, as the heatmap shows, never recovered to sustained double digits. Framing it as a one-line operational hiccup rather than a demand inflection was optimistic and — in hindsight — premature.

Episode 2 — Q3 FY25: "revenues below expectations." Two quarters after cutting the FY25 organic range from 6–8% to 5–6%, management cut it again to 4–4.5% and pivoted explicitly to a forward story.

"Our revenues were below expectations but we're raising earnings guidance… expect improving revenue in Q4 and in fiscal 2026 driven by MyDay." — Q3 FY25, August 2025

This quote captures the trade management has been running ever since: honest on EPS, aspirational on revenue re-acceleration. CVI sphere turned negative organic for the first time in the window. The stock fell roughly 13% the next session and triggered both the $89M reorganization and the activist campaigns that followed.

Episode 3 — Q4 FY25 / Q1 FY26: the reframe. Management replaced the growth-streak narrative with an earnings-consistency narrative.

"Closed FY25 ahead of consensus revenue, earnings, and free cash flow expectations… eight consecutive quarters of earnings beats." — Q4 FY25, December 2025

The reframe is executed cleanly: $89M of charges producing $50M/year of annualized savings, a $1B buyback expansion at depressed prices, a 3-year cumulative FCF target above $2.2B, and a 180 bps non-GAAP op-margin expansion already visible in Q1 FY26. Credible and tangible — but also a structural admission that the old growth rate is gone.

**Pattern.** Management misses revenue, beats EPS through cost-outs, raises FCF guidance, and reframes the story forward. Disciplined — but the organic growth forecast has been cut sequentially for three quarters, and FY26 guidance (4.5–5.5%) is already below the FY23–FY24 run-rate.

5. Guidance Track Record

FY23 and FY24 guides were beaten; FY25 is the break. The initial FY25 organic guide of 6–8% (midpoint 7%) landed at +4% — roughly 300 bps below the midpoint and 200 bps below the low end. EPS beat every year, including FY25 ($4.13 vs $3.92–4.02 guide).

Two successive cuts within one fiscal year — a signature of a growth story in transition, not an execution hiccup.

No Results

Credibility Score (out of 10)

Consecutive EPS Beats

FY25 Organic Cuts

**Credibility: 6 / 10.** Management delivered FY23 and FY24 above the initial guides and has beaten EPS for eight straight quarters. But the FY25 organic guide was cut twice and still landed 300 bps below the initial midpoint — the top-line forecast was optimistic, and the fertility slowdown was framed as a one-quarter ERP event when it turned out to be structural. The pivot to margin, FCF, and buybacks is executed tangibly (not vaporware), and the Q1 FY26 raise is real — but the organic growth narrative stays on probation until MyDay and MiSight deliver the re-acceleration management has promised for multiple quarters. Executionally competent; forecasting one to two quarters late on the deceleration.

6. What the Story Is Now

Cooper today is a mid-single-digit organic grower with expanding margins, returning cash, and an open strategic review — a fundamentally different pitch from the "high-single / low-double-digit grower with a fertility growth engine and a silicone-hydrogel flywheel" that framed FY22–FY24. Three things have been genuinely de-risked: balance sheet (net debt down, interest expense down 13% YoY, $2.3B revolver refinanced), earnings power (eight-quarter EPS beat streak, 180 bps op-margin expansion in Q1 FY26, $50M/yr of reorganization savings flowing), and capital return (buyback authorization expanded to $2.0B, 4.1M shares repurchased in FY25, Al White's personal $808K insider buy in December 2025). Three things still look stretched: the MyDay / MyDay Energys / MiSight acceleration story has been promised forward for multiple quarters and now needs to actually show up in CVI organic; tariffs are a persistent, widening GM drag that management has not solved; and the activist push from Jana Partners and Browning West — centred on separating CooperVision from CooperSurgical and on CooperSurgical's sub-par returns on more than $3B of capital deployed since 2017 — is a live governance risk that could drive a structural outcome management has not steered into.

Believe: the cost discipline, the FCF target, and the EPS floor. Discount: the "re-acceleration in FY26 driven by MyDay" line until at least two consecutive quarters of CVI organic back above +5%, and any claim that CooperSurgical can earn adequate returns on the fertility build-out without a structural change. The current story is simpler and more honest than the one pitched two years ago — which is itself an admission that the earlier story was more stretched than management disclosed at the time.